Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSE [NASD]
Sensei Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own0.30% Shs Outstand32.37M Perf Week-8.97%
Market Cap427.28M Forward P/E- EPS next Y-1.47 Insider Trans245.89% Shs Float28.05M Perf Month-14.89%
Income-20.20M PEG- EPS next Q-0.30 Inst Own9.89% Short Float2.04% Perf Quarter-
Sales- P/S- EPS this Y1.70% Inst Trans- Short Ratio1.95 Perf Half Y-
Book/sh- P/B- EPS next Y-15.90% ROA- Target Price- Perf Year-
Cash/sh0.51 P/C25.74 EPS next 5Y- ROE- 52W Range11.75 - 26.50 Perf YTD-30.16%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.19% Beta-
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low12.34% ATR0.89
Employees30 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)40.05 Volatility5.09% 7.03%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.15 Prev Close14.12
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume292.72K Price13.20
Recom1.40 SMA20-6.79% SMA50-18.72% SMA200-18.72% Volume42,773 Change-6.52%
Mar-01-21Initiated Piper Sandler Overweight $25
Mar-01-21Initiated Oppenheimer Outperform $36
Mar-01-21Initiated Citigroup Buy $30
Mar-01-21Initiated Berenberg Buy $27
Apr-05-21 08:00AM  
Mar-25-21 08:00AM  
Mar-22-21 08:00AM  
Mar-09-21 08:30AM  
Mar-05-21 03:30PM  
Feb-10-21 04:55PM  
Feb-09-21 11:08AM  
Feb-05-21 05:26PM  
Feb-04-21 05:56PM  
Feb-03-21 08:44PM  
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cambrian BioPharma Inc10% OwnerApr 13Buy14.002,00028,0004,809,544Apr 14 05:00 PM
Peyer JamesDirectorApr 13Buy14.002,00028,0004,809,544Apr 14 04:41 PM
Peyer JamesDirectorApr 07Buy14.002,00028,0004,807,544Apr 08 06:13 PM
Cambrian BioPharma Inc10% OwnerApr 07Buy14.002,00028,0004,807,544Apr 08 06:12 PM
Cambrian BioPharma Inc10% OwnerApr 01Buy14.001,00014,0004,805,544Apr 02 02:58 PM
Peyer JamesDirectorApr 01Buy14.001,00014,0004,805,544Apr 02 02:56 PM
Cambrian BioPharma Inc10% OwnerMar 30Buy12.002,00024,0004,804,544Mar 31 03:43 PM
Peyer JamesDirectorMar 30Buy12.002,00024,0004,804,544Mar 31 03:41 PM
Peyer JamesDirectorMar 24Buy14.123,75052,9504,802,544Mar 25 12:40 PM
Cambrian BioPharma Inc10% OwnerMar 24Buy14.123,75052,9504,802,544Mar 25 12:37 PM
Peyer JamesDirectorMar 23Buy14.3410,000143,4004,798,794Mar 24 04:21 PM
Cambrian BioPharma Inc10% OwnerMar 23Buy14.3410,000143,4004,798,794Mar 24 04:19 PM
Cambrian BioPharma Inc10% OwnerMar 22Buy15.022,18332,7894,788,794Mar 23 12:34 PM
Peyer JamesDirectorMar 22Buy15.022,18332,7894,788,794Mar 23 12:32 PM
Cambrian BioPharma Inc10% OwnerMar 18Buy15.2581712,4594,786,611Mar 19 03:51 PM
Peyer JamesDirectorMar 18Buy15.2581712,4594,786,611Mar 19 03:44 PM
Peyer JamesDirectorMar 08Buy15.251,00015,2494,785,794Mar 10 05:37 PM
Cambrian BioPharma Inc10% OwnerMar 08Buy15.251,00015,2494,785,794Mar 10 05:35 PM
Cambrian BioPharma Inc10% OwnerMar 05Buy13.758,000110,0004,784,794Mar 08 04:55 PM
Peyer JamesDirectorMar 05Buy13.758,000110,0004,784,794Mar 08 04:48 PM
Peyer JamesDirectorMar 04Buy14.122,00028,2504,776,794Mar 05 01:55 PM
Cambrian BioPharma Inc10% OwnerMar 04Buy14.122,00028,2504,776,794Mar 05 01:57 PM
Cambrian BioPharma Inc10% OwnerMar 03Buy15.853,00047,5504,774,794Mar 05 01:57 PM
Peyer JamesDirectorMar 03Buy15.853,00047,5504,774,794Mar 05 01:55 PM
Peyer JamesDirectorMar 02Buy16.253,00048,7504,771,794Mar 03 05:22 PM
Cambrian BioPharma Inc10% OwnerMar 02Buy16.253,00048,7504,771,794Mar 03 05:19 PM
Cambrian BioPharma Inc10% OwnerFeb 26Buy16.255,00081,2504,768,794Mar 02 04:15 PM
Peyer JamesDirectorFeb 26Buy16.255,00081,2504,768,794Mar 02 04:15 PM
Peyer JamesDirectorFeb 25Buy15.7912,000189,4804,763,794Feb 26 04:05 PM
Cambrian BioPharma Inc10% OwnerFeb 25Buy15.7912,000189,4804,763,794Feb 26 04:05 PM
Cambrian BioPharma Inc10% OwnerFeb 24Buy16.9119,000321,3824,751,794Feb 26 04:05 PM
Peyer JamesDirectorFeb 24Buy16.9119,000321,3824,751,794Feb 26 04:05 PM
Peyer JamesDirectorFeb 23Buy17.7920,300361,0704,732,794Feb 25 05:55 PM
Cambrian BioPharma Inc10% OwnerFeb 23Buy17.7920,300361,0704,732,794Feb 25 05:55 PM
Cambrian BioPharma Inc10% OwnerFeb 22Buy18.889,802185,0624,712,494Feb 24 08:32 PM
Peyer JamesDirectorFeb 22Buy18.889,802185,0624,712,494Feb 24 08:27 PM
Cambrian BioPharma Inc10% OwnerFeb 19Buy19.7711,786233,0094,702,692Feb 23 04:15 PM
Peyer JamesDirectorFeb 19Buy19.7711,786233,0094,702,692Feb 23 04:15 PM
Cambrian BioPharma Inc10% OwnerFeb 18Buy19.7575314,8724,690,906Feb 19 04:15 PM
Peyer JamesDirectorFeb 18Buy19.7575314,8724,690,906Feb 19 04:15 PM